Form 4: DiaMedica Therapeutics Director Randall Giuffre Reports Acquisition of Stock Options and Updated Shareholdings

DiaMedica Therapeutics Inc. Director Randall Michael Giuffre has reported the acquisition of 32,162 stock options with an exercise price of $4.11, alongside his updated beneficial ownership of common shares.

Summary

• Randall Michael Giuffre, a Director of DiaMedica Therapeutics Inc. (DMAC), filed a Form 4 statement detailing changes in his beneficial ownership.
• On June 1, 2025, Mr. Giuffre acquired 32,162 stock options to purchase common shares at an exercise price of $4.11 per share.
• These stock options will vest in four nearly equal quarterly installments over one year and have an expiration date of May 31, 2035.
• Following this transaction, Mr. Giuffre directly beneficially owns 392,412 voting common shares, which includes 4,146 voting common shares issuable upon settlement of deferred share units, 95,016 shares issuable upon settlement of deferred stock units, 164,890 voting common shares held jointly with his wife, and 128,360 voting common shares held individually.
• Additionally, he indirectly beneficially owns 25,573 voting common shares through 424822 Albert Ltd, where he has sole voting and dispositive power, and 21,070 voting common shares held by his spouse.
• His total direct beneficial ownership of derivative securities (stock options) is 32,162.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns the director's financial interests with the company's stock performance, indicating confidence in future growth.

Positives

• The acquisition of 32,162 stock options by a director indicates alignment of interests between management and shareholders, as the options gain value if the stock price increases.
• The exercise price of $4.11 for the newly acquired options provides a clear target for future stock performance.

Stakeholder Impact

• Shareholders: The acquisition of stock options by a director can be seen as a positive signal, aligning management's interests with shareholder value creation.

Next Steps

• The acquired stock options will vest in four nearly equal quarterly installments over one year from the transaction date of June 1, 2025.

Key Dates

Recommendation

Keywords

DiaMedica Therapeutics, DMAC, Form 4, SEC filing, insider trading, beneficial ownership, stock options, director ownership, equity compensation, Randall Giuffre